Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine + Ropivacaine vs Continuous Block in Shoulder Surgery
NCT05775861Recruiting
- Start
- Aug 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dexmedetomidine in postoperative pain and shoulder pain. Primary endpoint: Quality of Recovery-15 at 48 hours. Started Aug 2022; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
postoperative painshoulder pain
Beyond the preview
Go deeper on NCT05775861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775861.